Altered sphingoid base profiles in type 1 compared to type 2 diabetes

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Wei, Nancy ^a   Pan, Jessica ^b   Pop Busui, Rodica ^c   Othman, Alaa ^d   Alecu, Irina ^d   Hornemann, Thorsten ^d   Eichler, Florian S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Atypical sphingolipids; Biomarker; Deoxysphingolipids; Metabolic syndrome; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

1 DEOXYSPHINGANINE; 1 DEOXYSPHINGOLIPID; 1 DEOXYSPHINGOSINE; SPHINGOLIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 1-DEOXYSPHINGANINE; SPHINGOSINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; AGED; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; MIDDLE AGED;

ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; SPHINGOLIPIDS; SPHINGOSINE;

EID: 84976897938     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-161     Document Type: Article

References (9)

1. Cowart LA: Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol Metab 2009, 20: 34-42. 10.1016/j.tem.2008.09.004
2. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, Bandyopadhyay S, Jones KN, Kelly S, Shaner RL, Sullards CM, Wang E, Murphy RC, Barkley RM, Leiker TJ, Raetz CR, Guan Z, Laird GM, Six DA, Russell DW, McDonald JG, Subramaniam S, Fahy E, Dennis EA: Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010, 51: 3299-3305. 10.1194/jlr.M009449
3. Penno A, Reilly MM, Houlden H, Laura M, Rentsch K, Niederkofler V, Stoeckli ET, Nicholson G, Eichler F, Brown RH Jr, von Eckardstein A, Hornemann T: Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem 2010, 285(15):11178-11187. 10.1074/jbc.M109.092973
4. Eichler F, Hornemann T, McCampbell A, Kuljis D, Penno A, Vardeh D, Tamrazian E, Garofalo K, Lee H, Kini L, Selig M, Frosch M, Gable K, von Eckardstein A, Woolf CJ, Guan G, Harmon JM, Dunn TM, Brown RH: Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J Neurosci 2010, 29(46):14646-14651.
5. Auer-Grumbach M: Hereditary sensory neuropathy type I. Orphanet J Rare Dis 2008, 3: 7. 10.1186/1750-1172-3-7
6. Othman A, Rütti MF, Ernst D, Saely CH, Rein P, Drexel H, Porretta-Serapiglia C, Lauria G, Bianchi R, von Eckardstein A, Hornemann T: Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia 2012, 55: 421-431. 10.1007/s00125-011-2384-1
7. Bertea M, Rütti MF, Othman A, Marti-Juan J, Hersberger M, Von Eckardstein A, Hornemann T: Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis 2010, 9: 84. 10.1186/1476-511X-9-84
8. Hornemann T, Penno A, Rütti MF, Ernst D, Kivrak-Pfiffner F, Rohrer L, Von Eckardstein A: The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases. J Biol Chem 2009, 284: 26322-26330. 10.1074/jbc.M109.023192
9. Zitomer NC, Mitchell T, Voss KA, Bondy GS, Pruett ST, Garnier-Amblard EC, Liebeskind LS, Park H, Wang E, Sullards MC, Merrill AH Jr, Riley RT: Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxy-sphinganine: a novel category of bioactive 1-deoxy-sphingoid bases and 1-deoxy-dihydroceramides biosynthesized by mammalian cell lines and animals. J Biol Chem 2009, 284: 4786-4795. 10.1074/jbc.M808798200